SCHEMBL4631280

SCHEMBL4631280

O=C(c1cc(C(F)(F)F)cc(C(F)(F)F)c1)N1CCOC(CCO)(c2ccc(F)c(F)c2)C1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TACR2 P21452 1/20 0.49
CYP3A4 P08684 11/20 0.41
USP2 O75604 10/20 0.41
HSD17B10 Q99714 3/20 0.41
TSHR P16473 6/20 0.40
CYP2C9 P11712 6/20 0.40
CYP1A2 P05177 4/20 0.40
CYP2C19 P33261 3/20 0.40
HIF1A Q16665 4/20 0.39
CYP2D6 P10635 5/20 0.39
RHOC P08134 1/20 0.39
RHOA P61586 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39
ALOX15 P16050 1/20 0.39
MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL380714 0.92 USP2 (0.41) TACR2CYP3A4USP2HSD17B10TSHR
SCHEMBL380713 0.92 USP2 (0.41) TACR2CYP3A4USP2HSD17B10TSHR
SCHEMBL4864462 0.88 USP2 (0.42) CYP3A4USP2HSD17B10TSHRCYP2C9
SCHEMBL5115024 0.88 USP2 (0.42) CYP3A4USP2HSD17B10TSHRCYP2C9
SCHEMBL4631148 0.86 TACR2 (0.46) TACR2CYP3A4USP2HSD17B10TSHR
SCHEMBL4631267 0.86 TACR2 (0.62) TACR2CYP3A4USP2TSHRCYP1A2
SCHEMBL4631226 0.85 TACR2 (0.51) TACR2CYP3A4USP2HSD17B10TSHR
SCHEMBL5106731 0.83 TACR2 (0.39) TACR2CYP3A4USP2TSHRCYP2C9
SCHEMBL4631188 0.82 TACR2 (0.50) TACR2CYP3A4USP2HSD17B10TSHR
SCHEMBL7186563 0.82 TACR2 (0.49) TACR2CYP3A4TSHRCYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1923391-A1 Substituted heterocyclic compounds, method for preparing same and pharmaceutical compositions containing them. sanofi-aventis (FR) 2008-05-21 EP disclosed
EP-1688416-A1 Substituted heterocyclic compounds, their process of preparation and pharmaceutical compositions containing them Sanofi-Aventis (FR) 2006-08-09 EP disclosed
EP-1340754-A1 Substituted heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them SANOFI-SYNTHELABO (FR) 2003-09-03 EP disclosed
CN-1089764-C Substituted heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them SANOFI SYNTHESIZING LAB (FR) 2002-08-28 CN disclosed
EP-1156049-A1 Substituted heterocyclic compounds, their process of preparation and pharmaceutical compositions containing them SANOFI-SYNTHELABO (FR) 2001-11-21 EP disclosed
US-6242637-B1 USED IN TREATMENT INVOLVING THE TACHYKININ SYSTEM, SUCH AS PAIN, ALLERGY AND INFLAMMATION, CIRCULATORY, GASTROINTESTINAL, NEUROLOGICAL, AND NEUROPSYCHIATRIC DISORDERS SANOFI-SYNTHELABO (FR) 2001-06-05 US disclosed
US-6011154-A Substituted heterocyclic compounds, method of preparing them and pharmaceutical compositions in which they are present SANOFI (FR) 2000-01-04 US disclosed
US-5977359-A Substituted heterocyclic compounds, method of preparing them and pharmaceutical compositions in which they are present SANOFI (FR) 1999-11-02 US disclosed
US-5869663-A INTERMEDIATES FOR NEUROKININ RECEPTOR ANTAGONISTS SANOFI (FR) 1999-02-09 US disclosed
US-5780466-A DISORDERS ASSOCIATED WITH EXCESS TACHYKININS AND ALL NEUROKININ-DEPENDENT DISORDERS; ANALGESICS; RESPIRATORY, GASTROINTESTINAL, UROGENTIAL, IMMUNE, CARDIOVASCULAR AND CNS DISORDERS SANOFI (FR) 1998-07-14 US disclosed
US-5641777-A NEUROKININ RECEPTOR ANTAGONIST SANOFI (FR) 1997-06-24 US disclosed
WO-1996023787-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME SANOFI (FR) 1996-08-08 WO disclosed